JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Article

pubs.acs.org/JAFC

# Isomer-Specific Consumption of Galactooligosaccharides by Bifidobacterial Species

Kyle S. Peacock,[†,∥] L. Renee Ruhaak,[†,∥] Man Ki Tsui,[‡,#] David A. Mills,[‡,#,⊥] and Carlito B. Lebrilla*[,†,#]

[†]Department of Chemistry, [‡]Department of Viticulture and Enology, [#]Foods for Health Institute, and [⊥]Department of Food Science and Technology, University of California—Davis, One Shields Avenue, Davis, California 95616, United States

**ABSTRACT:** Prebiotics are nondigestible substrates that stimulate the growth of beneficial microbes in the human intestine. Galactooligosaccharides (GOS) are food ingredients that possess prebiotic properties, in particular, promoting the growth of bifidobacteria in situ. However, precise mechanistic details of GOS consumption by bifidobacteria remain poorly understood. Because GOS are mixtures of polymers of different lengths and linkages, there is interest in determining which specific structures provide prebiotic effects to potentially create better supplements. This paper presents a method comprising porous graphitic carbon separation, isotopic labeling, and mass spectrometry analysis for the structure-specific analysis of GOS isomers and their bacterial consumption rate. Using this strategy, the differential bacterial consumption of GOS by the bifidobacteria species *Bifidobacterium longum* subsp. *infantis*, *Bifidobacterium animalis* subsp. *lactis*, and *Bifidobacterium adolescentis* was determined, indicating that the use of specific GOS isomers in infant formula may provide enrichment of distinct species.

**KEYWORDS:** *galactooligosaccharide, Bifidobacteria, nanoHPLC, TOF mass spectrometry, prebiotics*

## INTRODUCTION

Human milk is often called the "perfect food". Bioactive components in milk, such as free oligosaccharides, have been shown to benefit the infant by stimulating the immune system, mimicking epithelial binding sites for pathogenic bacteria, and stimulating the growth of beneficial bacteria.[1−5] It is currently thought that the growth of these beneficial bacteria, often bifidobacteria, is the catalyst for a host of events that help safeguard the infant in the early stages of life. This notion has sparked research on understanding the consumption of human milk oligosaccharides (HMO) by different probiotic bifidobacteria species.[5−9] Interestingly, not all bifidobacterial species grow equally well on HMO. The infant-borne species *Bifidobacterium longum* subsp. *infantis* (*Bifidobacterium infantis*) grows much faster than several other bifidobacterial strains.[5] Moreover, *B. infantis* was shown to proliferate well on smaller HMO, which are the bulk of the free oligosaccharides present in human milk.[6]

In situations when human milk (and thus HMO) may not be available, there is a need for a synthetic substitute that can bestow the same advantages as mother's milk. Because the goal is to manipulate bacterial populations, glycans being considered have to be nondigestible by humans and resistant to degradation during gastrointestinal transit to reach the target organisms. The prospective glycans must also, upon reaching the colon, promote the growth of the beneficial bacteria in the infant gut and, thereby, partially emulate the benefits endowed by human milk.[10−13]

Viable targets have been oligosaccharide polymers, composed from either fructose or galactose. Fructooligosaccharides (FOS), polymers of fructose connected in a $\beta$2-1 manner, are extracted from fruits and plants, as well as enzymatically produced. Both smaller and longer chain fructans have been shown to stimulate bifidobacteria.[14] However, galactooligosaccharides (GOS) consist of a lactose core, which is elongated with galactose polymers, where the galactose residues may be linked using different glycosidic linkages ($\beta$1-3, $\beta$1-4, or $\beta$1-6). In contrast to FOS, which is a linear polymer, GOS structures may be branched, resulting in large structural heterogeneity.[15−18] On the basis of the natural occurrence of galactose in human milk oligosaccharides and their more branched structures, GOS are more often used as a substitute for HMO in infant formula.

The potential of GOS mixtures to stimulate bifidobacteria has been studied extensively, both in vivo and in vitro.[16,19−22] Recently, Davis et al.[23] showed that consumption of GOS resulted in a highly specific enrichment of bifidobacteria in adult subjects. Although such enrichments have been observed, exact mechanistic details of GOS consumption by bifidobacteria remain elusive. Van Leare et al. initially studied the consumption of GOS in *Bifidobacterium adolescentis* cultures,[22] and more recently, our group[19] evaluated the fermentation of GOS in four major bifidobacterial phylotypes: *B. adolescentis*, *Bifidobacterium breve*, *B. infantis*, and *B. longum* subsp. *longum* (*B. longum*). In both cases differential consumption of specific DPs of GOS was observed by the various bifidobacterial species. *B. infantis* deploys three (of the five) $\beta$-galactosidases, with different specificities, to cleave the different linkages present in GOS.[20] A recent study identified the genetic loci responsible for the transportation and consumption of GOS by *B. breve* and revealed the importance of an endogalactanase for the consumption of GOS with higher degrees of polymerization (DP).[24] These results provide some mechanistic insight into how GOS might differentially enrich different species and

Received: August 26, 2013
Revised: November 27, 2013
Accepted: December 8, 2013
Published: December 9, 2013

 © 2013 American Chemical Society 




**Figure 1.** Overlay of three total ion chromatograms obtained from analysis of GOS by nLC-chip-TOF-MS. Signal mainly corresponds to isomers with lengths from DP 3 to 5.

strains of bifidobacteria and help to produce a gut microbial population that emulates an infant fed human milk.[25]

GOS are composed of a galactose polymer bound to a lactose core. There is a wide variety of compositional isomers in a product mixture of GOS due to variation in the core disaccharide, in both composition and linkage, along with structural variation within subsequent galactose units attached to the core, resulting in a mixture of polymers of different lengths and linkages.[26] Therefore, there is interest in determining which specific structures are most selective to create more targeted prebiotic applications. Characterization of the individual GOS structures is traditionally performed with high-performance anion exchange chromatography (HPAEC) or NMR/GC-MS analysis, and these methods have been able to deduce the structure of smaller (di/trisaccharides) GOS.[22,26] Although this combination of methods is accurate, the time required for separation and the amount of sample necessary for GC-MS and NMR analyses may not always be available. More recently, a method comprising capillary electrophoresis with fluorescence detection was suggested for the analysis of galactooligosaccharides from food sources.[27] We recently introduced the use of MALDI-FTICR-MS for monitoring the consumption of GOS polymers by bacterial strains.[19] Although mass spectrometry techniques are well suited for the detection of oligosaccharides, the technology alone does not provide isomer specific information. Therefore, the combination of a separation technique with mass spectrometry is necessary for the structure-specific profiling of GOS.

Porous graphitized carbon (PGC) is a stationary phase that has been widely used for oligosaccharide analysis and has been shown to provide separation of isomers.[28−34] Thus far, PGC has not been applied for the separation of GOS. Here we report the use of PGC nHPLC-MS for the separation of galactooligosacchride isomers with DP from 3 to 5 for a commercially available mixture. To allow the determination of preferential consumption of individual isomers of GOS by bifidobacterial species, *B. animalis* subsp. *lactis*, *B. adolescentis*, and *B. longum* subsp. *infantis* were with GOS as the sole carbon source. Using an isotopic labeling method[35] in combination with nLC-PGC-TOF-MS, the consumption of specific GOS isomers was quantified and differential consumption patterns were observed.

## ■ MATERIALS AND METHODS

Commercially available Vivinal GOS mixture was obtained from FrieslandCampina Domo (Zwolle, The Netherlands). HPLC grade acetonitrile (ACN) was purchased from Honeywell Burdick & Jackson (Morristown, NJ, USA). Sodium borohydride (98%, $NaBH_4$) and sodium borodeuteride (98%, $NaBD_4$) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

**Reduction and Purification of GOS Samples.** Twenty-five microliter volumes of GOS, 0.5% (w/v), were reduced with sodium borohydride by mixing an equal volume of 2 M $NaBH_4$ and incubating at 65 °C for 2 h. An isotopic standard was produced by the reduction of a standard 0.5% (w/v) solution with 2 M $NaBD_4$. This standard was mixed with the fermented GOS samples to introduce an isotopically labeled control into the test sample.

After mixing, oligosaccharides were purified by solid-phase extraction using graphitized carbon (Extract-Clean SPE Carbo Cartridges, Grace, Deerfield, IL, USA) and eluted with 4 mL of 40% aqueous ACN. All samples were then dried under vacuum and reconstituted in water to a final concentration of 2 $\mu$g/uL. Samples were diluted 1:20 (100 ng/$\mu$L) before injection and analysis by nLC-chip-TOF-MS.

**Analysis of GOS by nLC-chip-TOF-MS.** GOS samples were analyzed using an Agilent series 6200 series nLC-chip-TOF-MS system. The chip used consists of a 40 nL enrichment column and a 43 × 0.75 mm i.d. analytical column, both packed with 5 $\mu$m particle sized PGC. The sample of interest (1 $\mu$L) was loaded onto the enrichment column isocratically via a capillary pump at a flow rate of 4.0 $\mu$L/min and then eluted using a nanoliter pump running at 0.3 $\mu$L/min. GOS separation was performed using a binary gradient consisting of an aqueous solvent A (3% acetonitrile/water (v/v) in 0.1% formic acid solution) and an organic solvent B (90% acetonitrile/water (v/v) in 0.1% formic acid solution) The gradient profile ramped from 0 to 16% B over 20 min, from 16 to 44% B for 10 min, and from 44 to 100% B over 15 min. The column was then conditioned for 10 min at 100% B and then equilibrated back to 0% B over a 20 min period. Samples were detected over an $m/z$ range of 300−3000 in the positive ionization mode. The data were analyzed using Agilent Mass Hunter Qualitative Analysis software, version B.03.01.

**Bacterial Growth Using GOS.** Strains representing three bifidobacterial species, *B. longum* subsp. *infantis* (ATCC15697), *B. adolescentis* (ATCC15703), and *B. animalis* subsp. *lactis* (UCD316), were obtained from the University of California—Davis Viticulture and Enology Culture Collection. Two microliters of each resulting overnight culture was used to inoculate 150 $\mu$L of modified MRS (mMRS) medium supplemented with 0.5% (w/v) GOS as the sole carbohydrate source, and another 2 $\mu$L was inoculated into mMRS without added sugar. The media were supplemented with 0.05% (w/v)




**Figure 2.** Separation of GOS isomers using PGC stationary phase; extracted ion chromatograms of DP 3−5 using TOF detection in the positive ionization mode. Separation of the isomers occurs with different efficacies: DP3 isomers span a 10 min window, whereas DP4 isomers span 8 min and DP5 isomers 5 min.

L-cysteine, and in all cases the cultures in the wells of the microtiter plates were covered with 30 μL of sterile mineral oil to avoid evaporation. The incubations were carried out at 37 °C in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI, USA). Cell growth was monitored in real time by assessing optical density (OD) at 600 nm using a BioTek PowerWave 340 plate reader (BioTek, Winooski, VT, USA) every 30 min preceded by 15 s of shaking at variable speed. When growth reached stationary phase, a 25 μL aliquot of the supernatant containing residual GOS was taken. The remaining GOS were then purified using SPE and subsequently analyzed with nLC-chip-TOF-MS. Each experiment was performed in triplicate.

**Data Analysis.** For each chromatogram obtained, the H/D ratio was calculated by using in-house software LC/MS Searcher.[35] In brief, the H/D ratio is calculated for Agilent data exported to an mzXML format. A library file that specifies the number of isomers, their retention times, and the theoretical relative intensity of the first isotope for that mass to the isotopic mass is provided to the program before processing. The apex of each peak is then searched within an area around the retention time given, and the H/D ratio is determined for the closest spectra. After extraction of the H/D ratio for each isomer, the average, standard deviation, and CV were determined using Excel (Microsoft Office Excel 2007). Using these values single-factor ANOVA was performed with an $F$ value of 0.05 (confidence level = 95%). Fischer's least significant difference method was applied to determine if consumption between species could be considered significant on an individual isomer basis.

## RESULTS AND DISCUSSION

**Separation of GOS with nLC-chip-TOF-MS Using PGC.** PGC is widely recognized for its ability to separate oligosaccharide isomers. In this work, PGC is for the first time employed for the separation of isomers of GOS. The GOS were reduced to avoid separation of anomers before separation with PGC liquid chromatography. The resulting total ion chromatogram (TIC) for three instrument replicates is depicted in Figure 1 and shows the overall GOS separation, which is efficiently achieved within 20 min.

Separation of the TIC into individual extracted ion chromatograms reveals that each individual DP observed shows a characteristic elution profile (Figure 2). GOS polymers are observed for DP3 [$M + H^+$ = 507.19], DP4 [$M + H^+$ = 669.24], DP5 [$M + H^+$ = 831.297611], and DP6 [$M + H^+$ = 993.35]; however, the major signals correspond to DP3, DP4, and DP5, consistent with previously reported experiments.[19] As depicted in Figure 2, 14 DP3 isomers elute between 4 and 14 min, 12 isomers of DP4 elute between 9 and 17 min, and 7 isomers of DP5 elute between 10 and 15 min. For each DP, the respective chromatogram displays a characteristic elution profile, which highlights the structural heterogeneity in the oligosaccharide polymer.

The separation and analysis of the GOS polymer mixture is highly reproducible. This is shown in Figure 1, where an




**Figure 3.** Systematic overview of the H/D ratio strategy. (A) First, consumed samples are reduced using sodium borohydride, whereas a standard sample is reduced with sodium borodeuteride. (B) Equal concentrations of sample/standard are mixed and analyzed by nLC-PGC-chip-TOF-MS. (C) The resulting spectra are corrected for the samples' isotopic distribution. The resulting intensities of the monoisotopic and first isotopic peak of the given sugar mass then represent the consumed sample and deuterated standard concentrations, respectively. (D) By comparing the intensity of the sample to the standard, a calibration curve was generated, which was used for calibration of the procedure.

overlay is depicted of three instrument replicates of the separation of GOS using PGC-TOF-MS. Previous work by our group, focusing on the stability of the nLC-PGC-chip-TOF method for the profiling of *N*-glycans for the development of biomarkers, has already indicated that the technology is highly stable.[36] Stability of the method is desirable, as multiple samples need to be compared.

Because PGC interacts with the oligosaccharides by interacting with three-dimensional cross sections of the molecule, it can be seen to lose the ability to effectively separate GOS polymers as they become longer and the unique structural characteristics average out. This can be seen by looking at the windows of elution for each of the DPs described above. For example, DP3 isomers spanned a 10 min window, whereas DP4 isomers spanned 8 min and DP5 isomers, 5 min. This results in larger coalescence of peaks seen at the higher DPs, suggesting that PGC may be less effective for the separation of very large GOS isomers.

**Quantification of GOS Using H/D Ratios.** Reductive isotopic labeling was used for the quantitation of the changes in relative abundance of GOS isomers. The procedure is outlined in Figure 3. The consumed GOS sample, after being used for the growth of bifidobacterial strains, would be reduced with sodium borohydride, whereas a standard sample of the original GOS mixture would be reduced with sodium borodeuteride and thus provide an isotopically labeled control that can be spiked into the test sample (Figure 3A). Mixing the two samples together provides a unique isotopic distribution (Figure 3B,C) that can be used to quantify the consumption of the GOS by different bacterial strains, as was previously shown for HMO consumption.[35]

To evaluate the accuracy of the relative quantitation of the GOS isomers, a calibration curve was generated. Equal amounts and concentrations of a standard GOS solution were reduced with either sodium borohydride or sodium borodeuteride. First, labeled and unlabeled samples were mixed in a 1:1 ratio followed by a 10% decrease in the unlabeled fraction for each subsequent mixture. The different mixtures were then analyzed using nHPLC-chip-TOF-MS. For each of the observed isomers from DP3 to DP5, the spectra were extracted from the optimum of the signal, and using in-house software, the isotopic distribution was corrected for the original C13 contribution from our test sample and subsequently used to determine the relative ratio of sample consumed in comparison to the

standard. The relative ratios were then plotted against the actual percentage to provide a linear response curve (Figure 3D). A linear equation was fitted and was shown to be linear with a coefficient of determination value of 0.98, indicating a good linear range and high accuracy of the method down to 10% of the original sample.

**Application to Bacterial Consumption.** To evaluate the potential of the proposed method, it was applied toward the determination of the consumption of GOS by three bifidobacterial strains: *B. infantis* (ATCC15697), *B. adolescentis* (ATCC15703), and *B. lactis* (UCD316). These strains were chosen because they can all grow on GOS but grow differentially on HMO; growth curves of the three bifidobacteria are shown in Figure 4. *B. infantis* ATCC15697 grows




**Figure 4.** Growth curves of the bifidobacteria used in this study: growth of *B. longum* subsp. *infantis* ATCC15697 (dashed line), *B. adolescentis* ATCC15703 (continuous line), and *B. animales* subsp. *lactis* UCD316 (dotted line) on GOS (0.05% w/v) in modified MRS medium. Samples for glycomic analyses were taken at early stationary phase for each of the three cultures.

vigorously on HMO[7] and contains a number of transport systems for various glycan substrates.[37] Conversely, *B. adolescentis* ATCC15703 and *B. lactis* UCD316 do not grow on HMO[7,38] and are rarely found in the breast-fed infant gut. The bacteria were grown in a medium in which the GOS mixture of interest was the sole source of carbon and each bifidobacterial strain was grown in biological triplicate. Growth was allowed to continue until the end of the exponential growth phase before the supernatant was extracted. Subsequently, the samples were reduced and mixed with an isotopically labeled standard (Figure 3) before analysis by nLC-chip-TOF-MS.

For each DP, the consumption of the individual isomers was determined according to the method described above and subsequently compared between the three species. For DP3, these results are shown in Figure 5. Interestingly, several of the DP3 structures were significantly consumed (e.g., 1 and 6), whereas other DP3 structures were only marginally consumed (e.g., 10 and 13). A single-factor ANOVA ($F = 0.05$) was used to determine if a significant difference existed in GOS consumption between the species. All isomers of DP3 except for 1, 3, and 6 were shown to differ significantly in their consumption between the three species. Differences among the consumption patterns of individual isomers between the three bifidobacteria species were then identified using least significant difference testing. Table 1 shows a summary of all the results for each of the DP. Statistical results are recorded as either a "yes", for a statistical significance, or a "no", for no statistical significance. Interestingly, only three of the DP3 isomers, none of the DP4, and two of the DP5 isomer structures did not show differences in consumption between the three species, indicating that the bifidobacteria each clearly have different preferences with regard to GOS consumption. Although different consumption patterns were observed for each of the strains, the consumption pattern of *B. lactis* seems more different compared to *B. infantis* and *B. adolescentis*. Some of the structures were clearly more consumed by *B. lactis* compared to the two other species (DP3-7, DP4-2, and DP4-6), whereas other structures were clearly less consumed (DP3-2, DP3-5, DP3-12, DP3-14, DP4-1, DP4-7, DP4-9, DP5-1, DP5-2, and DP5-7).

The larger oligosaccharides, after being consumed, may contribute to the lower mass oligosaccharides signal and potentially skew the results. To further assess this, the average consumption was calculated for all DP. Sixty-two percent of the DP3 isomers were consumed on average in comparison to only 35% of the DP5 structures, thus indicating that smaller oligosaccharides are preferentially consumed over the larger ones. This is in agreement with previous publications.[19]




**Figure 5.** Bacterial consumption of DP3 as determined using nLC-chip-TOF-MS and H/D ratio; bar graph representing corresponding H/D ratios for each of the DP3 isomers. Bars for *B. infantis* are blue, bars for *B. lactis* are red, and bars for *B. adolescentis* are green. Error bars represent the standard deviation calculated over the biological triplicates. For the EIC chromatogram depicting the elution and numerical annotation of the DP3 GOS isomers, see Figure 2. Differences in the consumption of individual isomers, between one or more species, could indicate a preference the species might have with regard to that particular structure.

**Table 1. Differential Consumption of GOS Structures by Bifidobacteria Species**

| | H/D ratio | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **DP3 Group Differences** | | | | | | | | | | | | | |
| species/isomer digested: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| *B. infantis* | 18 ± 11 | 4 ± 0 | 33 ± 6 | 18 ± 2 | 22 ± 2 | 6 ± 0 | 31 ± 2 | 34 ± 1 | 22 ± 1 | 59 ± 2 | | 32 ± 3 | 76 ± 4 | 35 ± 4 |
| *B. lactis* | 24 ± 0 | 73 ± 8 | 29 ± 14 | 35 ± 2 | 71 ± 3 | 7 ± 3 | 5 ± 1 | 41 ± 5 | 32 ± 13 | 75 ± 3 | | 76 ± 14 | 93 ± 6 | 66 ± 8 |
| *B. adolescentis* | 3 ± 3 | 4 ± 2 | 18 ± 3 | 7 ± 1 | 8 ± 2 | 9 ± 2 | 14 ± 2 | 33 ± 2 | 9 ± 1 | 74 ± 5 | | 35 ± 6 | 83 ± 7 | 24 ± 2 |
| significant difference in the group | no | yes | no | yes | yes | no | yes | yes | yes | yes | | yes | yes | yes |
| | **DP3 Species Differences** | | | | | | | | | | | | | |
| *infantis* to *lactis* | no | yes | no | yes | yes | no | yes | yes | no | yes | | yes | yes | yes |
| *infantis* to *adolescentis* | no | no | no | yes | yes | yes | yes | no | yes | yes | | no | no | yes |
| *lactis* to *adolescentis* | no | yes | no | yes | yes | no | yes | yes | yes | no | | yes | yes | yes |
| | **DP4 Group Differences** | | | | | | | | | | | | | |
| *B. infantis* | 32 ± 3 | 70 ± 2 | 25 ± 1 | 45 ± 1 | 37 ± 1 | 69 ± 1 | 23 ± 1 | 68 ± 4 | 44 ± 3 | 80 ± 4 | 48 ± 8 | 54 ± 9 | | |
| *B. lactis* | 96 ± 3 | 6 ± 0 | 74 ± 3 | 57 ± 2 | 76 ± 2 | 13 ± 1 | 71 ± 9 | 57 ± 3 | 106 ± 5 | 97 ± 4 | 73 ± 7 | 51 ± 16 | | |
| *B. adolescentis* | 43 ± 6 | 75 ± 2 | 49 ± 4 | 49 ± 4 | 73 ± 3 | 58 ± 1 | 23 ± 3 | 43 ± 2 | 47 ± 4 | 56 ± 3 | 26 ± 12 | 1 ± 1 | | |
| significant difference in the group | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | |
| | **DP4 Species Differences** | | | | | | | | | | | | | |
| *infantis* to *lactis* | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | no | | |
| *infantis* to *adolescentis* | yes | yes | yes | no | yes | yes | no | yes | no | yes | yes | yes | | |
| *lactis* to *adolescentis* | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | yes | | |
| | **DP5 Group Differences** | | | | | | | | | | | | | |
| species/isomer digested | 1 | 2 | 3 | 4 | 5 | 6 | 7 | | | | | | | |
| *B. infantis* | 41 ± 2 | 53 ± 2 | 64 ± 1 | 72 ± 1 | 58 ± 3 | 48 ± 1 | 54 ± 1 | | | | | | | |
| *B. lactis* | 84 ± 2 | 91 ± 3 | 64 ± 1 | 61 ± 3 | 88 ± 3 | 56 ± 1 | 89 ± 4 | | | | | | | |
| *B. adolescentis* | 58 ± 23 | 73 ± 12 | 64 ± 1 | 67 ± 12 | 75 ± 9 | 45 ± 7 | 52 ± 30 | | | | | | | |
| significant difference in the group | yes | yes | no | no | yes | yes | yes | | | | | | | |
| | **DP5 Species Differences** | | | | | | | | | | | | | |
| *infantis* to *lactis* | yes | yes | no | no | yes | yes | yes | | | | | | | |
| *infantis* to *adolescentis* | no | yes | no | no | yes | no | no | | | | | | | |
| *lactis* to *adolescentis* | yes | yes | no | no | yes | yes | yes | | | | | | | |

Galactooligosacchride isomers have been shown to be quickly and reproducibly separated using nHPLC with a PGC stationary phase. A quantitative method using isotopic labeling was used to determine the fermentation of individual galactooligosacchride isomers and was shown to provide accurate results. The method was applied to three bifidobacterial species, and significant differences in the consumption of particular isomers was determined through ANOVA and least significant difference testing. It is anticipated that the methodology described here will further expedite progress toward understanding the GOS structural moieties responsible for the resulting prebiotic effect.

The gut microbiota of breast-fed infants is often dominated by specific infant-borne bifidobacterial species, whereas formula-fed infants often have a more diverse adult-like bifidobacterial composition.[14] In this study, it is demonstrated that the individual GOS structures are consumed at different rates by the different bifidobacteria, and the consumption of specific oligosaccharides will likely result in the presence of specific bifidobacterial species in the infant's gut. Therefore, our results provide a conceptual basis for production of tailored GOS products targeted toward the preferences of specific bifidobacterial species or even strains. Further structural elucidation of the different GOS isomers may therefore reveal structural features that will provide guidance for specific enrichment of certain bifidobacterial species in the infant gut.

## ■ AUTHOR INFORMATION

### Corresponding Author

*Mailing address: Department of Chemistry, University of California—Davis, One Shields Avenue, Davis, CA 95616, USA. E-mail: cblebrilla@ucdavis.edu. Phone: 1 (530) 752-0504. Fax: 1 (530) 754-8995.

### Author Contributions

[‖]These authors contributed equally to the work.

### Funding

This work was supported in part by DSM Food Specialties as well as National Institutes of Health Awards R01HD061923 and R01AT007079. D.A.M. acknowledges funding from the Shields Endowed Chair in Dairy Food Science.

### Notes

The authors declare no competing financial interest.

## ■ REFERENCES

(1) Versalovic, J.; Wilson, M. *Therapeutic Microbiology: Probiotics and Related Strategies*; ASM Press: Washington, DC, 2008; p xv + 395 pp.

(2) Gnoth, M. J.; Kunz, C.; Kinne-Saffran, E.; Rudloff, S. Human milk oligosaccharides are minimally digested in vitro. *J. Nutr.* **2000**, *130*, 3014−3020.

(3) McVeagh, P.; Miller, J. B. Human milk oligosaccharides: only the breast. *J. Paediatr. Child Health* **1997**, *33*, 281−286.

(4) Ward, R. E.; Ninonuevo, M.; Mills, D. A.; Lebrilla, C. B.; German, J. B. In vitro fermentation of breast milk oligosaccharides by *Bifidobacterium infantis* and *Lactobacillus gasseri*. *Appl. Environ. Microbiol.* **2006**, *72*, 4497−4499.

(5) Ward, R. E.; Ninonuevo, M.; Mills, D. A.; Lebrilla, C. B.; German, J. B. In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria. *Mol. Nutr. Food Res.* **2007**, *51*, 1398−1405.

(6) LoCascio, R. G.; Ninonuevo, M. R.; Freeman, S. L.; Sela, D. A.; Grimm, R.; Lebrilla, C. B.; Mills, D. A.; German, J. B. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. *J. Agric. Food Chem.* **2007**, *55*, 8914−8919.

(7) Locascio, R. G.; Ninonuevo, M. R.; Kronewitter, S. R.; Freeman, S. L.; German, J. B.; Lebrilla, C. B.; Mills, D. A. A versatile and scalable strategy for glycoprofiling bifidobacterial consumption of human milk oligosaccharides. *Microb. Biotechnol.* **2009**, *2*, 333−342.

(8) Ruiz-Moyano, S.; Totten, S. M.; Garrido, D.; Smilowitz, J. T.; German, J. B.; Lebrilla, C. B.; Mills, D. A. Variation in consumption of human milk oligosaccharides by infant-gut associated strains of *Bifidobacterium breve*. *Appl. Environ. Microbiol.* **2013**, DOI: 10.1128/AEM.01843-13.

(9) Asakuma, S.; Hatakeyama, E.; Urashima, T.; Yoshida, E.; Katayama, T.; Yamamoto, K.; Kumagai, H.; Ashida, H.; Hirose, J.; Kitaoka, M. Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. *J. Biol. Chem.* **2011**, *286*, 34583−34592.

(10) Fooks, L. J.; Fuller, R.; Gibson, G. R. Prebiotics, probiotics and human gut microbiology. *Int. Dairy J.* **1999**, *9*, 53−61.

(11) Gibson, G. R.; Roberfroid, M. B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J. Nutr.* **1995**, *125*, 1401−1412.

(12) Gopal, P. K.; Sullivan, P. A.; Smart, J. B. Utilisation of galacto-oligosaccharides as selective substrates for growth by lactic acid bacteria including *Bifidobacterium lactis* DR10 and *Lactobacillus rhamnosus* DR20. *Int. Dairy J.* **2001**, *11*, 19−25.

(13) Jia, W.; Li, H.; Zhao, L.; Nicholson, J. K. Gut microbiota: a potential new territory for drug targeting. *Nat. Rev. Drug Discov.* **2008**, *7*, 123−129.

(14) Haarman, M.; Knol, J. Quantitative real-time PCR assays to identify and quantify fecal *Bifidobacterium* species in infants receiving a prebiotic infant formula. *Appl. Environ. Microbiol.* **2005**, *71*, 2318−2324.

(15) Angus, F.; Smart, S.; Shortt, C. Prebiotic ingredients with emphasis on galacto-oligosaccharides and fructo-oligosaccharides. In *Probiotic Dairy Products*; Blackwell Science: Oxford, UK, 2007; pp 120−137.

(16) Macfarlane, G. T.; Steed, H.; Macfarlane, S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. *J. Appl. Microbiol.* **2008**, *104*, 305−344.

(17) Park, A. R.; Oh, D. K. Galacto-oligosaccharide production using microbial $\beta$-galactosidase: current state and perspectives. *Appl. Microbiol. Biotechnol.* **2010**, *85*, 1279−1286.

(18) Ganzle, M. G. Enzymatic synthesis of galacto-oligosaccharides and other lactose derivatives (hetero-oligosaccharides) from lactose. *Int. Dairy J.* **2012**, *22*, 116−122.

(19) Barboza, M.; Sela, D. A.; Pirim, C.; Locascio, R. G.; Freeman, S. L.; German, J. B.; Mills, D. A.; Lebrilla, C. B. Glycoprofiling bifidobacterial consumption of galacto-oligosaccharides by mass spectrometry reveals strain-specific, preferential consumption of glycans. *Appl. Environ. Microbiol.* **2009**, *75*, 7319−7325.

(20) Garrido, D.; Ruiz-Moyano, S.; Jimenez-Espinoza, R.; Eom, H. J.; Block, D. E.; Mills, D. A. Utilization of galactooligosaccharides by *Bifidobacterium longum* subsp. *infantis* isolates. *Food Microbiol.* **2013**, *33*, 262−270.

(21) Silk, D. B.; Davis, A.; Vulevic, J.; Tzortzis, G.; Gibson, G. R. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. *Aliment. Pharmacol. Ther.* **2009**, *29*, 508−518.

(22) Van Laere, K. M.; Abee, T.; Schols, H. A.; Beldman, G.; Voragen, A. G. Characterization of a novel $\beta$-galactosidase from *Bifidobacterium adolescentis* DSM 20083 active towards transgalactooligosaccharides. *Appl. Environ. Microbiol.* **2000**, *66*, 1379−1384.

(23) Davis, L. M.; Martinez, I.; Walter, J.; Goin, C.; Hutkins, R. W. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. *PLoS One* **2011**, *6*, e25200.

(24) O'Connell Motherway, M.; Kinsella, M.; Fitzgerald, G. F.; van Sinderen, D. Transcriptional and functional characterization of genetic elements involved in galacto-oligosaccharide utilization by *Bifidobacterium breve* UCC2003. *Microb. Biotechnol.* **2013**, *6*, 67−79.

(25) Oozeer, R.; van Limpt, K.; Ludwig, T.; Ben Amor, K.; Martin, R.; Wind, R. D.; Boehm, G.; Knol, J. Intestinal microbiology in early life: specific prebiotics can have similar functionalities as human-milk oligosaccharides. *Am. J. Clin. Nutr.* **2013**, *98*, 561S−571S.
(26) Coulier, L.; Timmermans, J.; Bas, R.; Van Den Dool, R.; Haaksman, I.; Klarenbeek, B.; Slaghek, T.; Van Dongen, W. In-depth characterization of prebiotic galacto-oligosaccharides by a combination of analytical techniques. *J. Agric. Food Chem.* **2009**, *57*, 8488−8495.
(27) Albrecht, S.; Schols, H. A.; Klarenbeek, B.; Voragen, A. G.; Gruppen, H. Introducing capillary electrophoresis with laser-induced fluorescence (CE-LIF) as a potential analysis and quantification tool for galactooligosaccharides extracted from complex food matrices. *J. Agric. Food Chem.* **2010**, *58*, 2787−2794.
(28) Ruhaak, L. R.; Deelder, A. M.; Wuhrer, M. Oligosaccharide analysis by graphitized carbon liquid chromatography-mass spectrometry. *Anal. Bioanal. Chem.* **2009**, *394*, 163−174.
(29) Ninonuevo, M.; An, H.; Yin, H.; Killeen, K.; Grimm, R.; Ward, R.; German, B.; Lebrilla, C. Nanoliquid chromatography-mass spectrometry of oligosaccharides employing graphitized carbon chromatography on microchip with a high-accuracy mass analyzer. *Electrophoresis* **2005**, *26*, 3641−3649.
(30) Chu, C. S.; Ninonuevo, M. R.; Clowers, B. H.; Perkins, P. D.; An, H. J.; Yin, H.; Killeen, K.; Miyamoto, S.; Grimm, R.; Lebrilla, C. B. Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. *Proteomics* **2009**, *9*, 1939−1951.
(31) Wu, S.; Grimm, R.; German, J. B.; Lebrilla, C. B. Annotation and structural analysis of sialylated human milk oligosaccharides. *J. Proteome Res.* **2011**, *10*, 856−868.
(32) Wu, S.; Tao, N.; German, J. B.; Grimm, R.; Lebrilla, C. B. Development of an annotated library of neutral human milk oligosaccharides. *J. Proteome Res.* **2010**, *9*, 4138−4151.
(33) Froehlich, J. W.; Barboza, M.; Chu, C. S.; Lerno, L. A., Jr.; Clowers, B. H.; Zivkovic, A. M.; German, J. B.; Lebrilla, C. B. Nano-LC-MS/MS of glycopeptides produced by non-specific proteolysis enables rapid and extensive site-specific glycosylation determination. *Anal. Chem.* **2011**, *83*, 5541−5547.
(34) Hua, S.; Nwosu, C. C.; Strum, J. S.; Seipert, R. R.; An, H. J.; Zivkovic, A. M.; German, J. B.; Lebrilla, C. B. Site-specific protein glycosylation analysis with glycan isomer differentiation. *Anal. Bioanal. Chem.* **2012**, *403*, 1291−1302.
(35) Strum, J. S.; Kim, J.; Wu, S.; De Leoz, M. L.; Peacock, K.; Grimm, R.; German, J. B.; Mills, D. A.; Lebrilla, C. B. Identification and accurate quantitation of biological oligosaccharide mixtures. *Anal. Chem.* **2012**, *84*, 7793−7801.
(36) Ruhaak, L. R.; Taylor, S. L.; Miyamoto, S.; Kelly, K.; Leiserowitz, G. S.; Gandara, D.; Lebrilla, C. B.; Kim, K. Chip-based nLC-TOF-MS is a highly stable technology for large scale high-throughput analyses. *Anal. Bioanal. Chem.* **2013**, *405*, 4953−4958.
(37) Garrido, D.; Kim, J. H.; German, J. B.; Raybould, H. E.; Mills, D. A. Oligosaccharide binding proteins from *Bifidobacterium longum* subsp. *infantis* reveal a preference for host glycans. *PLoS One* **2011**, *6*, e17315.
(38) Underwood, M. A.; Kalanetra, K. M.; Bokulich, N. A.; Lewis, Z. T.; Mirmiran, M.; Tancredi, D. J.; Mills, D. A. A comparison of two probiotic strains of bifidobacteria in premature infants. *J. Pediatr.* **2013**, *163*, 1585−1591e9.